Резолюция Совета экспертов «Лечение пациентов с хроническим вирусным гепатитом С – новые возможности и перспективы»
В.П. Чуланов, Абдурахманов Джамал Тинович, V. S. Adonyeva et al. · Клиническая инфектология и паразитология · 2025
Cited by 0 works. doi:10.34883/pi.2025.14.4.042 Open-access PDF
Authors
- В.П. Чуланов
- Абдурахманов Джамал Тинович
- V. S. Adonyeva
- V.A. Bakhtina
- Бессонова Елена Николаевна
- Богомолов Павел Олегович
- А.С. Дмитриев
- А.Г. Зуева
- М. В. Маевская
- Сагалова Ольга Игоревна
- А. И. Симакова
- V.A. Khabudaev
References
- Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
- Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
- Twelve‐week ravidasvir plus ritonavir‐boosted danoprevir and ribavirin for non‐cirrhotic HCV genotype 1 patients: A phase 2 study
- LBP-012 Multicenter, open-Label, randomized non-inferiority study comparing 8-week vs 12-week Sofosbuvir/Ravidasvir treatment for non-cirrhotic chronic hepatitis C patients (EASE trial)